Shares of Simulations Plus (NASDAQ:SLP) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price target of $18.75 for the company and are expecting that the company will post $0.11 EPS for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 85 out of 265 based on the ratings given to related companies.
A number of research analysts recently commented on SLP shares. Zacks Investment Research lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. BidaskClub upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Saturday, February 24th. Finally, ValuEngine upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd.
SLP traded up $0.05 on Friday, reaching $15.30. The company had a trading volume of 55,603 shares, compared to its average volume of 46,161. Simulations Plus has a fifty-two week low of $10.55 and a fifty-two week high of $17.45. The firm has a market cap of $263.71, a P/E ratio of 45.00 and a beta of -0.56.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Tuesday, January 9th. The technology company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.01. Simulations Plus had a net margin of 23.78% and a return on equity of 24.56%. The business had revenue of $7.07 million for the quarter, compared to analyst estimates of $6.57 million. analysts anticipate that Simulations Plus will post 0.4 earnings per share for the current year.
In related news, Chairman Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.13, for a total value of $298,405.00. Following the transaction, the chairman now owns 5,482,916 shares in the company, valued at approximately $88,439,435.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 33.45% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Macquarie Group Ltd. bought a new stake in Simulations Plus in the 3rd quarter valued at about $315,000. Northern Trust Corp boosted its holdings in Simulations Plus by 248.7% in the 2nd quarter. Northern Trust Corp now owns 145,018 shares of the technology company’s stock valued at $1,791,000 after purchasing an additional 103,435 shares during the period. Bank of Montreal Can bought a new stake in Simulations Plus in the 4th quarter valued at about $104,000. GSA Capital Partners LLP boosted its holdings in Simulations Plus by 118.7% in the 3rd quarter. GSA Capital Partners LLP now owns 47,110 shares of the technology company’s stock valued at $730,000 after purchasing an additional 25,571 shares during the period. Finally, Santa Monica Partners LP bought a new stake in Simulations Plus in the 4th quarter valued at about $532,000. 33.93% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/zacks-simulations-plus-slp-given-18-75-average-price-target-by-brokerages.html.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Get a free copy of the Zacks research report on Simulations Plus (SLP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.